Lifemd Stock Earnings Reports

LifeMD reported a strong start to 2026: Q1 revenue of $50.2M (above guidance) and a record net addition of ~42,000 telehealth subscribers, ending the quarter with >365,000 subscribers. Key growth drivers: weight management (nearly 100,000 weight management patients; sequential sign-up growth ~120% from Q4; benefits from oral GLP-1s and branded therapies), rapid early traction in women's health (subscriber count grew >7x vs. Q4 with >80% on-therapy retention), and RexMD (≈215,000 active patients; ED still core while sleep and other categories grow). Operational highlights include gross margin expansion (~420 bps to 88%) driven by in-house pharmacy and lower fulfillment/shipping costs, aggressive but productive front-loaded marketing in Q1 (peak for the year) and normalization expected in Q2, and active deployment of AI across clinical and back-office workflows to drive provider efficiency and margin gains (expected to show up more in H2 2026). Pharmacy and payer progress: a 22,500 sq ft, 50-state licensed affiliated pharmacy processing ~20,000 prescriptions/month; covered lives expanded to ~112M and expected to reach ~230M imminently; Medicare GLP-1 Bridge (launching July 1) could expand access to Medicare patients. Financial posture: Q1 adjusted EBITDA loss of ~$4.5M (in line with guidance); GAAP net loss $9.6M; cash $34.5M, no debt, $30M undrawn revolver. Management reaffirmed full-year 2026 guidance of $220M–$230M revenue and $12M–$17M adjusted EBITDA, and reiterated expectation of >$250M run-rate revenue and >$25M run-rate adjusted EBITDA by Q4. Management frames the strategy around building an integrated virtual care platform (care, pharmacy, insurance, AI) focused on durable, higher-quality revenue and long-term margin expansion.